Form 4: Twist Bio CFO Sells Shares for Tax Obligations

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 887 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (TWST), reported a sale of common stock.
• On November 21, 2025, Laponis sold 887 shares of TWST common stock at a price of $26.5035 per share.
• The transaction was a "sell to cover" sale, mandated by the company's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units.
• This sale was not a discretionary trade by the reporting person.
• Following the transaction, Laponis beneficially owns 142,769 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, which is neutral in sentiment. It does not indicate a change in management's outlook on the company's prospects.

Positives

• The transaction was non-discretionary, indicating it was not a voluntary sale by the CFO based on personal market outlook.
• The sale was executed to cover tax withholding obligations, a standard practice for equity compensation.

Negatives

• A reduction in the CFO's direct beneficial ownership by 887 shares, although for a non-discretionary reason.

Industry Context

This is a routine insider transaction related to equity compensation and tax obligations, common across all industries, including biotechnology. It does not reflect specific industry trends or competitive positioning.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the CFO's confidence or the company's fundamentals.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell to cover' transaction by the CFO to satisfy tax obligations related to RSU vesting. Such transactions are common and do not typically reflect management's discretionary view on the company's future performance. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Twist Bioscience, TWST, Adam Laponis, CFO, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Equity Compensation, Biotechnology